Survodutide
Also known as: BI 456906
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Who's worth your money for Survodutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (95) of 5 scored sellers
$99.00 · 12mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$78.00 · 10mg · 99.4% purity
Most tested
4 independent COAs on file
$720 · 6mg · 99.8% purity
Average price
$22.92/mg
Sellers
23
45-day trend
+7.5%
15 of 23 sellers have a current price· 4 stale hidden· 6 unverified hidden
Top Merit pick
🇺🇸 Profound Aminos95via Disclosed Labs · 23h ago
$8.25/mg -64% vs avg$99.00
12mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 23h ago
$10.00/mg -56.4% vs avg$99.99
10mg
no purityBuy code Orbitrex10 · 10% off - 🇺🇸 Hydro Research Peptides91
✓ verified at source · 23h ago
$120.00/mg +423.6% vs avg$720
6mg
- 🇺🇸 EZ Peptides85
✓ verified at source · 23h ago
$7.80/mg -66% vs avg$78.00
10mg
- 🇭🇰 zztai Peptide Ltd43
✓ verified at source · 23h ago
$25.70/mg +12.1% vs avg$257
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Survodutide
Get one email when the market actually moves — no newsletter, no noise.
About Survodutide
CAS
2805997-46-8
Molecular formula
C192H289N47O61
Typical dose range
0.3–2.7 mg once weekly subcutaneous (clinical trials; Phase II/III dose-escalation)
Half-life
~6 days
COAs for Survodutide
23 third-party tests across 6 vendors. Each card links to the full report.
For
Survodutide
by Profound Aminos· batch Yellow Cap
For
Survodutide
by Real Peptides· batch Clear Cap/Purple Crimp
For
Suvrodutide
by Kimera Chems· batch KC-SVD-BLK1
For
Survodutide
by Skye Peptides· batch SV25-12-001
For
Survodutide
by Ruo Bio· batch sur001
For
Survodutide
by Kimera Chems· batch KC-SVD-RED1
For
Survodutide
by Skye Peptides· batch SV25-06-001
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by Profound Aminos· batch 2025-01-23
For
Survodutide
by Hydro Research Peptides· batch 2024-08-05
For
Survodutide
by Optima Supply· batch 2024-08-05
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
For
Survodutide
by Optima Supply· batch Survodutide-6033
For
Survodutide
by Peptidology· batch 1671
For
Suvrodutide
by Kimera Chems· batch KC-SVD-RED1
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
Purity not on file
For
Survodutide
by Ruo Bio
20 citations indexed for Survodutide
Study · 2026
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.
review · 2026
How does survodutide work? Plain language review of a potential new medication for obesity and liver disease
What is this review about? This review provides an overview of a medication called survodutide. Survodutide is not yet approved for use but is currently being tested to treat people living with obesity , as well as those living with MASH (metabolic dysfunction-associated steatohepatitis).
Study · 2026
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial
Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist with the potential to induce greater weight reductions than GLP-1R mono-agonists.
Study · 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases.
Study · 2026
Survodutide Once Weekly for the Treatment of Adults with Obesity
Background Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.
review · 2026
Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis
Background Metabolism-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide.